Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Letrozole in Postmenopausal Breast Cancer
NCT00237211Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2001
- Primary completion
- Oct 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole in breast cancer, sponsored by Novartis. Primary endpoints: Safety during treatment and Response Rate during treatment. Started Jun 2001; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00237211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237211.